Korean journal of neurotrauma [Korean J Neurotrauma] 2023 Jun 20; Vol. 19 (2), pp. 162-176. Date of Electronic Publication: 2023 Jun 20 (Print Publication: 2023).

Publisher: Korean Neurotraumatology Society Country of Publication: Korea (South) NLM ID: 101584658 Publication Model: eCollection Cited Medium: Print ISSN: 2234-8999 (Print) Linking ISSN: 22348999 NLM ISO Abbreviation: Korean J Neurotrauma Subsets: PubMed not MEDLINE

Competing Interests: Conflict of Interest: The authors have no financial conflicts of interest.
Mannitol, derived from mannose sugar, is crucial in treating patients with elevated intracranial pressure (ICP). Its dehydrating properties at the cellular and tissue levels increase plasma osmotic pressure, which is studied for its potential to reduce ICP through osmotic diuresis. While clinical guidelines support mannitol use in these cases, the best approach for its application continues to be debated. Important aspects needing further investigation include: 1) bolus administration versus continuous infusion, 2) ICP-based dosing versus scheduled bolus, 3) identifying the optimal infusion rate, 4) determining the appropriate dosage, 5) establishing fluid replacement plans for urinary loss, and 6) selecting monitoring techniques and thresholds to assess effectiveness and ensure safety. Due to the lack of adequate high-quality prospective research data, a comprehensive review of recent studies and clinical trials is crucial. This assessment aims to bridge the knowledge gap, improve understanding of effective mannitol use in elevated ICP patients, and provide insights for future research. In conclusion, this review aspires to contribute to the ongoing discourse on mannitol application. By integrating the latest findings, this review will offer valuable insights into the function of mannitol in decreasing ICP, thereby informing better therapeutic approaches and enhancing patient outcomes.
(Copyright © 2023 Korean Neurotraumatology Society.)